Sunshine Biopharma Inc [NASDAQ: SBFM] slipped around -0.12 points on Tuesday, while shares priced at $1.84 at the close of the session, down -6.12%.
Sunshine Biopharma Inc stock is now -38.87% down from its year-to-date (YTD) trading value. SBFM Stock saw the intraday high of $2.13 and lowest of $1.8 per share. The company’s 52-week high price is 3.90, which means current price is +57.36% above from all time high which was touched on 04/02/25.
Compared to the average trading volume of 546.48K shares, SBFM reached a trading volume of 10430100 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sunshine Biopharma Inc [SBFM]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SBFM shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SBFM stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 0.33, with the Price to Cash per share for the same quarter was set at 2.26.
How has SBFM stock performed recently?
Sunshine Biopharma Inc [SBFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.17. With this latest performance, SBFM shares gained by 26.90% in over the last four-week period, additionally plugging by 32.37% over the last 6 months – not to mention a drop of -38.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SBFM stock in for the last two-week period is set at 54.61, with the RSI for the last a single of trading hit 0.1615, and the three-weeks RSI is set at 0.1325 for Sunshine Biopharma Inc [SBFM]. The present Moving Average for the last 50 days of trading for this stock 1.5867, while it was recorded at 1.8880 for the last single week of trading, and 1.7666 for the last 200 days.
Sunshine Biopharma Inc [SBFM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sunshine Biopharma Inc [SBFM] shares currently have an operating margin of -14.95% and a Gross Margin at 32.59%. Sunshine Biopharma Inc’s Net Margin is presently recorded at -17.35%.
Sunshine Biopharma Inc (SBFM) Capital Structure & Debt Analysis
According to recent financial data for Sunshine Biopharma Inc. ( SBFM), the Return on Equity (ROE) stands at -25.65%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -20.59%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Sunshine Biopharma Inc’s Return on Invested Capital (ROIC) is -23.90%, showcasing its effectiveness in deploying capital for earnings.
Sunshine Biopharma Inc (SBFM) Efficiency & Liquidity Metrics
Based on Sunshine Biopharma Inc’s (SBFM) latest financial statements, the Debt-to-Equity Ratio is 0.04%, indicating its reliance on debt financing relative to shareholder equity.
Sunshine Biopharma Inc (SBFM) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Sunshine Biopharma Inc. (SBFM) effectively leverages its workforce, generating an average of -$121346.15 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.00% and a Quick Ratio of 2.66%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Sunshine Biopharma Inc [SBFM]
With the latest financial reports released by the company, Sunshine Biopharma Inc posted -0.94/share EPS, while the average EPS was predicted by analysts to be reported at -535/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 534.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SBFM.
Insider trade positions for Sunshine Biopharma Inc [SBFM]
There are presently around $2.65%, or 2.73%% of SBFM stock, in the hands of institutional investors.
